ConductScience.org, home

Paper35923902

Joint Modeling of Incidence of Unfavorable Outcomes and Change in Viral Load Over Time Among Adult HIV/AIDS Patients on Second-Line Anti-Retroviral Therapy, in Selected Public Hospitals of Addis Ababa, Ethiopia.

Zakaria HF and 4 others. HIV AIDS (Auckl), 2022. Cited by 1 paper, by iCite.

Cite this record

ConductScience Library. Joint Modeling of Incidence of Unfavorable Outcomes and Change in Viral Load Over Time Among Adult HIV/AIDS Patients on Second-Line Anti-Retroviral Therapy, in Selected Public Hospitals of Addis Ababa, Ethiopia. Papers, record 35923902. Release papers-2026-11-12-0.1.0, 12 Nov 2026. https://conductscience.org/library/papers/35923902

Download JSON
Sources
11 sources
Release
papers-2026-11-12-0.1.0

Paper

PubMed's record of the paper, with iCite's citation figures. No abstract is shown.

Title
Joint Modeling of Incidence of Unfavorable Outcomes and Change in Viral Load Over Time Among Adult HIV/AIDS Patients on Second-Line Anti-Retroviral Therapy, in Selected Public Hospitals of Addis Ababa, Ethiopia.
PubMed
Journal
HIV AIDS (Auckl)
PubMed
Year
2022
PubMed
Publication types
Journal Article
PubMed
Citations, by iCite
1
iCite
Relative citation ratio, by iCite
0.15
iCite
Revised in PubMed
2022-08-05
PubMed

Authors5

The authors in the order PubMed's record lists them, with the ORCID iDs it states.

OrderAuthorForenameKindORCID iD
1Zakaria HFHamdi Fekredinhttps://orcid.org/0000-0001-6751-4944
2Ayele TATadesse Awoke
3Kebede SASewnet Ademhttps://orcid.org/0000-0001-7750-7596
4Jaldo MMMesfin Menzahttps://orcid.org/0000-0002-2886-0147
5Lajore BABereket Abrhamhttps://orcid.org/0000-0002-5296-7163

Source PubMed

Download CSV of authors

Topics0

NLM's MeSH indexing of the paper, its major topics first.

None in this release.

References22

The papers the reference list in PubMed's record names, those in our copy of PubMed, in the list's order.

OrderPMIDTitleJournalYearIn PapersSource
124312889Early outcome of second line antiretroviral therapy in treatment-experienced human immunodeficiency virus positive patients.Perspect Clin Res2013https://conductscience.org/library/papers/24312889PubMed
231489067Incidence and determinants of mortality among adult HIV infected patients on second-line antiretroviral treatment in Amhara region, Ethiopia: a retrospective follow up study.Pan Afr Med J2019https://conductscience.org/library/papers/31489067PubMed
326765104Retention in care among HIV-positive patients initiating second-line antiretroviral therapy: a retrospective study from an Ethiopian public hospital clinic.Glob Health Action2016https://conductscience.org/library/papers/26765104PubMed
433790656Influence of Lost to Follow Up from Antiretroviral Therapy Among Retroviral Infected Patients at Tuberculosis Centers in Public Hospitals of Benishangul-Gumuz, Ethiopia.HIV AIDS (Auckl)2021https://conductscience.org/library/papers/33790656PubMed
528594295Long-term outcomes of second-line antiretroviral treatment in an adult and adolescent cohort in Myanmar.Glob Health Action2017https://conductscience.org/library/papers/28594295PubMed
626572102Outcome of patients on second line antiretroviral therapy under programmatic condition in India.BMC Infect Dis2015https://conductscience.org/library/papers/26572102PubMed
721406048HIV treatment adherence, drug resistance, virologic failure: evolving concepts.Infect Disord Drug Targets2011https://conductscience.org/library/papers/21406048PubMed
832606835Increased Virological Failure and Determinants Among HIV Patients on Highly Active Retroviral Therapy in Adigrat General Hospital, Northern Ethiopia, 2019: Hospital-Based Cross-Sectional Study.Infect Drug Resist2020https://conductscience.org/library/papers/32606835PubMed
925590271Efficacy of second-line antiretroviral therapy among people living with HIV/AIDS in Asia: results from the TREAT Asia HIV observational database.J Acquir Immune Defic Syndr2015https://conductscience.org/library/papers/25590271PubMed
1033743748Incidence and predictors of early loss to follow up among patients initiated on protease inhibitor-based second-line antiretroviral therapy in southwestern Uganda.AIDS Res Ther2021https://conductscience.org/library/papers/33743748PubMed
1128329393
Virological Outcomes of Second-line Protease Inhibitor-Based Treatment for Human Immunodeficiency Virus Type 1 in a High-Prevalence Rural South African Setting: A Competing-Risks Prospective Cohort Analysis.
Clin Infect Dis2017https://conductscience.org/library/papers/28329393PubMed
1226512561Second-Line HIV Therapy Outcomes and Determinants of Mortality at the Largest HIV Referral Center in Southern Vietnam.Medicine (Baltimore)2015https://conductscience.org/library/papers/26512561PubMed
1332986756
Incidence and factors associated with treatment failure among HIV infected adolescent and adult patients on second-line antiretroviral therapy in public hospitals of Northern Ethiopia: Multicenter retrospective study.
PLoS One2020https://conductscience.org/library/papers/32986756PubMed
1424028937Factors associated with attrition, mortality, and loss to follow up after antiretroviral therapy initiation: data from an HIV cohort study in India.Glob Health Action2013https://conductscience.org/library/papers/24028937PubMed
156354290Sample-size formula for the proportional-hazards regression model.Biometrics1983https://conductscience.org/library/papers/6354290PubMed
1631288748Incidence and predictors of second-line antiretroviral treatment failure among adults living with HIV in Amhara region: a multi-centered retrospective follow-up study.BMC Infect Dis2019https://conductscience.org/library/papers/31288748PubMed
1731356613Second-line HIV treatment failure in sub-Saharan Africa: A systematic review and meta-analysis.PLoS One2019https://conductscience.org/library/papers/31356613PubMed
1825472544Short term adherence tool predicts failure on second line protease inhibitor-based antiretroviral therapy: an observational cohort study.BMC Infect Dis2014https://conductscience.org/library/papers/25472544PubMed
1927402780Protease Inhibitor Resistance in the First 3 Years of Second-Line Antiretroviral Therapy for HIV-1 in Sub-Saharan Africa.J Infect Dis2016https://conductscience.org/library/papers/27402780PubMed
2024498093Predictors of mortality among patients enrolled on antiretroviral therapy in Aksum hospital, northern Ethiopia: a retrospective cohort study.PLoS One2014https://conductscience.org/library/papers/24498093PubMed

See all 22 referencesDownload CSV of references

Cited by1

The papers in our copy of PubMed whose reference list names this one, newest first. iCite, which reads more sources, counts 1 citation.

PMIDTitleJournalYearIn Papers
38654969Virological Suppression and its Predictors Among HIV/AIDS Patients on Antiretroviral Therapy in Ethiopia: Systematic Review and Meta-analysis.Open Forum Infect Dis2024https://conductscience.org/library/papers/38654969

Source PubMed

Download CSV of cited by

Genes1

The genes the Gene search release ties to the paper: Swiss-Prot's references first, then PubTator's text mining.

GeneNCBI Gene IDLinked byIn Genes
CD4920PubTator's text mininghttps://conductscience.org/library/genes/920

Source NCBI Gene

Download CSV of genes

Data dates

The date of each source this release read.

PubMed
2026-11-06
PubMed
iCite
2026-11-05
iCite
PMC's ID file
2026-11-05
PMC's ID file
NIH RePORTER's grant and paper links
2026-11-01
NIH RePORTER's grant and paper links
Trials
2026-11-12
Gene search
2026-11-11
Pipelines
2026-09-18

None in this release

  • Grants
  • Trials
  • Comments and corrections
  • Drugs
  • Data

Sources 11

  • ChEMBL, through Open TargetsCC BY-SA 3.0
  • ClinicalTrials.govNo license stated
  • HGNCCC0
  • iCiteCC BY 4.0
  • NCBI GenePublic domain (US government)
  • NIH RePORTER's grant and paper linksPublic domain
  • Open TargetsCC0 1.0
  • PMC's ID filePublic domain (US government)
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0
Each source's terms
  • ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • ClinicalTrials.govnone stated
  • HGNCCC0: https://www.genenames.org/about/license/
  • iCiteCC BY 4.0
  • NCBI GeneNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • NIH RePORTER's grant and paper linksPublic domain (NIH RePORTER)
  • Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
  • PMC's ID fileNone named for the file. NCBI says information created by or for the US government on its site is in the public domain, and asks that NLM be acknowledged: https://www.ncbi.nlm.nih.gov/home/about/policies/
  • PubMedNLM's terms
  • PubTator 3Public domain
  • UniProtCC BY 4.0. UniProt's licence file: "All databases and documents in the UniProt FTP directory may be copied and redistributed freely, without advance permission, provided that this copyright statement is reproduced with each copy." UniProt asks that users cite its latest paper: The UniProt Consortium, UniProt: the Universal Protein Knowledgebase in 2025, Nucleic Acids Research 53:D609-D617, https://doi.org/10.1093/nar/gkae1010. Read on 9 Nov 2026 at https://www.uniprot.org/help/license

ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.

For software

Read this paper from software.

The record and each of its lists are JSON, twenty rows a page. No key.

GET https://conductscience.org/api/papers/v1/35923902

GET https://conductscience.org/api/papers/v1/35923902/references?page=2